Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
Join us on SATURDAY, JULY 16th, 2022, for the 2022 Targeted Therapies Patient Forum
This virtual program is presented Live Online from 10 AM - 4 PM EST
In this 8th annual live patient forum, leading thoracic oncologists from around the world as well as lung cancer patients who are active within the patient advocacy community discuss subjects relevant to all targets as well as breakout sessions on rare mutations.
This 6-hour live virtual webinar is an opportunity for lung cancer patients and caregivers to hear from experts and participate in live virtual question and answer sessions. The forum offers panel discussions, live Q&A sessions, and breakout sessions focused on rare mutations such as EGFR, ALK, ROS, RET and KRAS. This event is free but registration is required and limited. For more information visit the AGENDA and the FACULTY.
Foro de Pacientes de Terapias Dirigidas en Español!
Únase a nosotros el SÁBADO, 30 de julio de 2022, 09:00 a. m., hora del este.
Este programa virtual se presenta en vivo en línea a partir de las 9 a. m. EST.
Únase a nosotros para el segundo Foro Anual de Pacientes de Terapias Dirigidas. Este evento virtual en vivo está diseñado específicamente para la comunidad de cáncer de pulmón de habla hispana. El evento de medio día invitará a los asistentes a enviar preguntas en tiempo real, creando una conversación con los pacientes durante este evento virtual en vivo y abordando las preocupaciones específicas de la comunidad de habla hispana.
Este seminario web virtual en vivo de 2 horas es una oportunidad para que los pacientes con cáncer de pulmón y los cuidadores en la comunidad de cáncer de pulmón de habla hispana escuchen a profesores expertos de los Estados Unidos, Colombia y Costa Rica. El evento ofrece paneles de discusión y sesiones de preguntas y respuestas en vivo que cubren la terapia dirigida general, así como mutaciones como EGFR, ALK y otras. Este evento es gratuito, pero el registro es obligatorio y limitado. La agenda completa estará disponible pronto.
Para más información visita la Agenda y la Facultad
Registration for the Spanish Targeted Therapies Patient Forum is now open! Join us on SATURDAY,
Jul 30, 2022, 09:00 AM Eastern Time, This virtual program is presented Live Online starting at 9 AM EST.
Join us for the 2nd Annual Targeted Therapies Patient Forum. This live virtual event is specifically designed for the Spanish-speaking lung cancer community. The half-day event will engage attendees to submit questions in real time, creating a conversation with patients during this live virtual event and addressing the specific concerns of the Spanish-speaking community. This 2-hour live virtual webinar is an opportunity for lung cancer patients and caregivers in the Spanish speaking lung cancer community to hear from expert faculty from the United States, Columbia and Costa Rica. The event offers panel discussions and live Q&A sessions covering general targeted therapy as well as mutations such as EGFR, ALK and others. This event is free but registration is required and limited. The full agenda willl be available soon.
More information will be available soon!
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…